Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Antiviral Clinical Trial for Long Covid-19
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 90
- Registration Number
- NCT06511063
- Locations
- 🇺🇸
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York, United States
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 265
- Registration Number
- NCT05470491
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT04966429
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
The Role of Home Packs of HIV PEPSE in High Risk Individuals
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 139
- Registration Number
- NCT04965662
- Locations
- 🇬🇧
Guy's & St. Thomas' NHS Foundation Trust, London, Greater London, United Kingdom
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 120
- Registration Number
- NCT04789616
- Locations
- 🇨🇦
Dalhousie University, Halifax, Nova Scotia, Canada
🇨🇦Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario, Canada
🇨🇦Parkwood Institute, London, Ontario, Canada
Maraviroc in Patients With Moderate and Severe COVID-19
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT04435522
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
- Conditions
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 20
- Registration Number
- NCT03274804
- Locations
- 🇩🇪
National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
- Conditions
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 90
- Registration Number
- NCT03129113
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧Royal Free Hospital, London, United Kingdom
🇬🇧Royal London Hospital, London, United Kingdom
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 30
- Registration Number
- NCT02961829
- Locations
- 🇧🇷
CCDI, Sao Paulo, SP, Brazil
Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2016-10-14
- Target Recruit Count
- 25
- Registration Number
- NCT02934022
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.